NCI-2022-01956

A Phase I/IIa Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD7789, an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Participants With Advanced or Metastatic Solid Tumors

This phase I/IIa study aims to evaluate the safety, pharmacokinetics, and efficacy of a new drug, AZD7789, that can help the immune system better recognize and attack cancer cells, in participants with advanced or metastatic solid tumors. The study will assess the safety, effectiveness, and how well the treatment works

phase I/IIa: A study that assesses the safety, effectiveness, and how well the treatment works

pharmacokinetics: Pharmacokinetics studies how medicines move around in the body, including how they are absorbed, distributed, broken down, and removed.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT04931654

Clinical Trial Site: Sinai

To see all available clinical trials click here.